Castle Biosciences anticipates surpassing FY24 revenue guidance, showing growth in test reports.

From Nasdaq.: 2025-01-12 22:23:27

Castle Biosciences Inc. expects to exceed its full-year 2024 revenue guidance of $320 million – $330 million. In the fourth quarter of 2024, the company delivered 24,071 total test reports, up from 20,284 in the same period of 2023. Overall, in 2024, Castle Biosciences delivered 96,071 total test reports, compared to 70,429 in 2023. This achievement demonstrates the company’s dedication to providing value to shareholders and advancing healthcare through innovative tests that guide patient care.



Read more at Nasdaq.: Castle Biosciences Expects To Meet Or Exceed Top End Of FY24 Revenue Guidance